Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report 2025

This Endoscopic Retrograde Cholangiopancreatography (ERCP) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The endoscopic retrograde cholangiopancreatography (ERCP) market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.87%. The growth during the historical period can be attributed to the increasing prevalence of chronic gastrointestinal diseases, expanded applications of ERCP, a rising incidence of pancreatic cancer, growing government investments, and an increase in medical tourism.

The endoscopic retrograde cholangiopancreatography (ERCP) market size is expected to see strong growth in the next few years. It will grow to $2.6 billion in 2029 at a compound annual growth rate (CAGR) of 8.58%. The growth forecast for this period is driven by the rising prevalence of gastrointestinal conditions, an increasing incidence of cancer, heightened investment focus, a growing occurrence of pancreatic duct conditions, and rising demand for endoscopes. Key trends expected include technological advancements, partnerships for research and development, the expansion of healthcare infrastructure, increased government healthcare initiatives, and the development of advanced ERCP products.

The rising prevalence of gastrointestinal conditions is anticipated to drive the growth of the endoscopic retrograde cholangiopancreatography (ERCP) market. These conditions encompass a wide range of disorders affecting the gastrointestinal (GI) tract, including the mouth, esophagus, stomach, intestines, rectum, anus, and accessory organs such as the liver, gallbladder, and pancreas. Factors such as dietary changes, an aging population, antibiotic use, lifestyle habits, and environmental influences contribute to the increasing incidence of these conditions. ERCP provides a minimally invasive solution for diagnosing and treating bile and pancreatic duct issues, including gallstones, strictures, tumors, and infections. For example, the American Cancer Society estimated in January 2024 that approximately 26,890 new cases of stomach cancer would occur in the United States, with around 10,880 deaths expected. As gastrointestinal conditions become more common, the demand for ERCP procedures continues to grow.

Companies in the ERCP market are advancing procedures by developing innovative technologies, such as cholangioscope systems, for enhanced diagnosis and treatment. These systems provide high-resolution imaging of the bile and pancreatic ducts, improving therapeutic outcomes. In July 2024, Penlon Limited introduced the VedVision Cholangioscope Direct Visualization System, a cutting-edge device offering precise imaging for ERCP procedures. Its features include a 2 mm accessory channel and a dedicated guidewire channel, along with accessories such as biopsy forceps, stone extraction baskets, cytology brushes, and polypectomy snares, enhancing diagnostic and therapeutic capabilities.

In October 2022, OmniVision Technologies Inc., a semiconductor manufacturer based in the United States, collaborated with AdaptivEndo LLC to develop a unified platform for hybrid and single-use endoscopes. This platform is designed for use across various medical specialties, including gastroenterology, hepatology, urology, and gynecology, enabling a more streamlined approach to procedures such as endoscopic retrograde cholangiopancreatography (ERCP) and other endoscopic techniques. AdaptivEndo LLC, also based in the United States, specializes in single-use endoscopy devices that combine the functionalities of endoscopic ultrasound (EUS) and ERCP, offering enhanced versatility and efficiency in clinical practice.

Major players in the endoscopic retrograde cholangiopancreatography (ERCP) market are Medtronic plc, Fujifilm Holdings Corporation, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Ottomed Endoscopy, W. L. Gore & Associates Inc., Streis plc, Cook Group, KARL STORZ SE & Co. KG, CONMED Corporation, PENTAX Medical Inc., AMBU Inc., Samsung Medison Co. Ltd., Medi-Globe GmbH, Telemed System Inc., Micro-Tech Endoscopy Inc., Hobbs Medical Inc., Shaili Endoscopy Pvt. Ltd.

North America was the largest region in the endoscopic retrograde cholangiopancreatography (ERCP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endoscopic retrograde cholangiopancreatography (ERCP) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endoscopic retrograde cholangiopancreatography (ERCP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic and therapeutic medical procedure that integrates endoscopy with X-ray imaging to address conditions affecting the bile ducts, gallbladder, and pancreas. The process involves inserting a flexible, illuminated tube (endoscope) through the mouth into the small intestine, enabling physicians to diagnose and treat issues such as blockages or stones.

The primary products used in ERCP include endoscopes, endotherapy devices, visualization systems, and energy devices. Endoscopes are flexible tubes with a light and camera, allowing healthcare professionals to visualize the internal organs, particularly the digestive tract, during procedures such as ERCP. The procedure addresses various disease indications, including gastroesophageal reflux disease (GERD), gastrointestinal cancer, Barrett's esophagus, bile duct diseases, peptic ulcer disease, Crohn's disease, intestinal pseudo-obstruction, Ogilvie syndrome, and others. ERCP applications include biliary sphincterotomy, biliary dilatation, biliary stenting, pancreatic sphincterotomy, pancreatic duct dilatation, and pancreatic duct stenting. The key end users are hospitals and clinics, ambulatory surgery centers, and other healthcare facilities.

The endoscopic retrograde cholangiopancreatography (ERCP) market research report is one of a series of new reports that provides endoscopic retrograde cholangiopancreatography (ERCP) market statistics, including endoscopic retrograde cholangiopancreatography (ERCP) industry global market size, regional shares, competitors with endoscopic retrograde cholangiopancreatography (ERCP) market share, detailed endoscopic retrograde cholangiopancreatography (ERCP) market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopic retrograde cholangiopancreatography (ERCP) industry. This endoscopic retrograde cholangiopancreatography (ERCP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endoscopic retrograde cholangiopancreatography (ERCP) market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, post-operative, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The endoscopic retrograde cholangiopancreatography (ERCP) market also includes sales of biliary stents, guidewires, and catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.